SRNE - Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
- Sorrento Therapeutics ( NASDAQ: SRNE ) said that a pivotal study of its candidate abivertinib in non-small cell lung cancer demonstrated an overall response rate of 56.5% .
- In addition, results showed that 11 patients had complete responses ("CR") for a CR rate of 5.3% and median overall survival of 28.2 months.
- The patients enrolled in the trial were heavily pretreated.
- Abivertinib, a third-generation EGFR inhibitor, selectively inhibits EGFR-activating and resistant mutations with ~300-fold greater potency as compared with wild-type EGFR.
- Sorrento ( SRNE ) said that due to the data, it is closing the study and preparing for a pre-New Drug Applicaiton meeting with the US FDA.
- Check out why Seeking Alpha contributor SimeOne Trading sees Sorrento ( SRNE ) as a hold.
For further details see:
Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC